BioSpace News Archive

Morphic Therapeutic

Morphic Holding Inc is a biopharmaceutical company applying its insights into integrins to discover and develop a pipeline of oral small-molecule integrin therapeutics.
Oncorus

Oncorus is focused on realizing the full promise of IV-administered, self-amplifying RNA medicines to transform outcomes for cancer patients.
Denali Therapeutics Inc.

Denali Therapeutics is dedicated to defeating neurodegenerative diseases by breaking through historical barriers in scientific research and clinical development in order to deliver safe and effective medicines to patients and families.
Astellas Gene Therapies

Astellas Gene Therapies is an Astellas Center of Excellence developing genetic medicines with the potential to deliver transformative value for patients.
Career Advice

Executives Share Top Tips for a Successful Career Journey

Four executives with collective decades spent at BMS, Roche, Astellas, Eli Lilly and more gave their insights on navigating a biopharma career during a Monday DIA panel in San Diego.

June 19, 2024
·
4 min read
·
Chantal Dresner
Job Trends

5 Top Companies Hiring Quality Assurance Jobs

Looking for quality assurance jobs in the biopharma industry? Check out these five top companies hiring life sciences professionals like you.

June 19, 2024
·
1 min read
·
Angela Gabriel
Press Releases

WACKER & CordenPharma Enter Pandemic Readiness on 1 June 2024 After Successful Expansion & Qualification

June 19, 2024
·
5 min read
MicuRx To Present New Data At 7th World Bronchiectasis Conference

Shanghai MicuRx Pharmaceutical Co., Ltd. announced 3 new studies will be presented at the 7th World Bronchiectasis Conference, taking place from July 4 - 6, 2024 in Dundee, Scotland.

June 19, 2024
·
2 min read
Policy

European Commission grants Sobi® Marketing Authorisation for ALTUVOCT™ for treatment of haemophilia A

Sobi® announced the European Commission has granted Marketing Authorisation for ALTUVOCT™, for the treatment and prevention of bleeds and perioperative prophylaxis in haemophilia A. ALTUVOCT is a high-sustained factor VIII replacement therapy for all ages and any disease severity.

June 19, 2024
·
7 min read
Drug Development

Medivir selects global CRO partner for upcoming phase 2b study in HCC with fostrox + Lenvima and initiates study feasibility

Medivir AB announced that it has selected a global CRO partner for the planned phase 2b study evaluating fostroxacitabine bralpamide + Lenvima® vs Lenvima alone in second line HCC.

June 19, 2024
·
4 min read